FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:FRX - CA31447P1009 - Common Stock
FRX.CA Key Statistics, Chart & Performance
The current stock price of FRX.CA is 10.16 CAD. In the past month the price decreased by -18.39%. In the past year, price increased by 16.25%.
FRX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 602.23M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 404.82M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 183.31M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 78.41M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 25.86 | 49.99M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 32.66M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.73M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.86M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 13.05M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.57M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About FRX.CA
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What does FENNEC PHARMACEUTICALS INC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
What is the stock price of FENNEC PHARMACEUTICALS INC today?
The current stock price of FRX.CA is 10.16 CAD. The price decreased by -4.6% in the last trading session.
Does FRX stock pay dividends?
FRX.CA does not pay a dividend.
How is the ChartMill rating for FENNEC PHARMACEUTICALS INC?
FRX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for FRX.CA stock?
11 analysts have analysed FRX.CA and the average price target is 19.53 CAD. This implies a price increase of 92.26% is expected in the next year compared to the current price of 10.16.
What is FENNEC PHARMACEUTICALS INC worth?
FENNEC PHARMACEUTICALS INC (FRX.CA) has a market capitalization of 346.96M CAD. This makes FRX.CA a Small Cap stock.
FRX.CA Technical Analysis
FRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA. The financial health of FRX.CA is average, but there are quite some concerns on its profitability.
FRX.CA Financial Highlights
Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS decreased by -475% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FRX.CA Forecast & Estimates
11 analysts have analysed FRX.CA and the average price target is 19.53 CAD. This implies a price increase of 92.26% is expected in the next year compared to the current price of 10.16.
For the next year, analysts expect an EPS growth of -227846112347928100% and a revenue growth -20.4% for FRX.CA